Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial.

Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial to evaluate efficacy and safety of its novel siRNA asset for treatment of chronic hepatitis B infection.

Ribocure Pharmaceuticals AB, a pioneering Swedish biotech company and the international research center of Ribo Life Science Ltd, focused on development of cutting-edge RNA therapeutics, is delighted to announce that we have received Authorisation for a Phase II clinical trial to study efficacy and safety of RBD1016 in patients with chronic HBV infection through the newly launched European Union Clinical Trials Information System (CTIS). This Authorisation represents a significant milestone for the company as it marks our first Authorisation based on our proprietary siRNA platform within the EU and a crucial step forward in advancing our novel therapeutics towards the global market.

The Phase II study will assess efficacy and safety of our promising investigational drug RBD1016, a GalNAc-conjugated siRNA molecule based on our proprietary Ribo-GalSTARTM, targeting the X gene of hepatitis B virus. RBD1016 has already shown high potency and potential class-leading durability in a Ph1b study in target patient population. With this Ph2 study, we will further evaluate its potential for functional cure of this devastating disease still affecting millions of patients around the globe.

“We are thrilled to have received this Authorisation and one notable achievement in this process was the swift and efficient submission through CTIS system, within less than a month from the CTIS implementation date, the application was successfully submitted,” commented Prof Li-Ming Gan, CEO of Ribocure Pharmaceuticals and R&D President of Ribo Life Science Ltd.

“This momentous occasion is a testament to the dedication and expertise of our team. We are excited to embark on this journey and further validate the potential of our cutting-edge RNA therapeutics. We are deeply impressed by the high-quality feedback and the impressive speedy and efficient regulatory review process. I truly believe our advanced technology under guidance of this new world-leading regulatory process will make Sweden/EU a competitive place to be for bringing life-saving novel therapies to patients in need”.

Share on social media

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
Contact information to the Data Protection Officer (DPO):
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
E-mail: dpo@ribocure.com